［1］ 辛培源,杨振宇,包国强.胆道肿瘤复发转移和预后评估新思路:CTCs及FGFR2研究进展［J］.疑难病杂志,2022,21(5):552-556.
XIN PY,YANG ZY,BAO GQ.Research progress of CTCs and FGFR2 in recurrence,metastasis and prognosis assessment of biliary tract tumors［J］.Chinese Journal of Difficult and Complicated Cases,2022,21(5):552-556.
［2］ 吕文杰,刘颖斌.胆道恶性肿瘤药物治疗进展［J］.上海医药,2022,43(S02):920-929.
LYU WJ,LIU YB.New pharmacological treatment in biliary tract cancers［J］.Shanghai Medical & Pharmaceutical Journal,2022,43(S02):920-929.
［3］ 李年丰,冯思佳.NCCN肝胆肿瘤临床实践指南(2021.V1)胆管肿瘤诊治的解读［J］.肝胆胰外科杂志,2021,33(9):607-613.
LI NF,FENG SJ.Interpretation of NCCN Clinical Practice Guidelines in Hepatoliliary Cancers (2021,version) for diagnosis and treatment of cholangiocarcinoma［J］.Journal of Hepatopancreatobiliary Surgery,2021,33(9):607-613.
［4］ 张进儒,郑安婕,刘海明,等.放化疗联合靶向药物治疗晚期胆道恶性肿瘤的效果和安全性［J］.临床医学研究与实践,2020,5(9):320-323.
ZHANG JR,ZHENG AJ,LIU HM,et al.Efficacy and safety of radiotherapy and chemotherapy combined with targeted drugs in the treatment of advanced biliary malignant tumor［J］.Clinical Research and Practice,2020,5(9):320-323.
［5］ 李一鸣,邱红.晚期胆道系统恶性肿瘤的化疗及靶向治疗药物进展［J］.临床外科杂志,2020,32(8):505-510.
LI YM,QIU H.Advances in chemotherapy and targeted therapy for advanced biliary system malignancies［J］.Journal of Clinical Surgery,2020,32(8):505-510.
［6］ 博伦,张琼,王祥旭,等.血管内皮生长因子/血管内皮生长因子受体通路在胆管细胞癌发生发展及治疗中的作用［J］.临床肝胆病杂志,2020,36(8):401-405.
BO L,ZHANG Q,WANG XX,et al.Role of the VEGF/VEGFＲ pathways in the development，progression，and treatment of cholangiocellular carcinoma［J］.Journal of Clinical Hepatology,2020,36(8):401-405.
［7］ 何勤思,钟军,郑智.靶向RAS信号通路的抗肿瘤药物治疗［J］.实用癌症杂志,2013,33(7):456-461.
HE QS,ZHONG J,ZHENG Z.Antitumor drug therapy targeting RAS signaling pathway［J］.The Practical Journal of Cancer,2013,33(7):456-461.
［8］ 甄自力,沈哲民,孙培龙.胆道系统恶性肿瘤免疫治疗的研究进展及展望［J］.中国免疫学杂志,2021,37(22):521-526.
ZHEN ZL,SHEN ZM,SUN PL.Research progress and prospects of immunotherapy for biliary tract cancers［J］.Chinese Journal of Immunology,2021,37(22):521-526.
［9］ 马泰,顾康生.进展期胆道肿瘤内科治疗新靶点研究进展［J］.肝胆外科杂志,2019,27(3):419-423.
MA T,GU KS.Research progress on new targets for medical treatment of advanced biliary tract tumors［J］.Journal of Hepatobiliary Surgery,2019,27(3):419-423.
［10］ 张雪,刘国东,林群,等.siRNA靶向沉默ZFX基因对肝内胆管癌细胞生物学功能的影响［J］.安徽医科大学学报,2018,53(11):500-505.
ZHANG X,LIU GD,LIN Q,et al.siRNA targeted silencing ZFX gene on intrahepatic cholangiocarcinoma cells effects on biological functions［J］.Acta Universitatis Medicinalis Anhui,2018,53(11):500-505.
［11］ ABOU-ALFA GK,SAHAI V,HOLLEBECQUE A,et al.Pemigatinib for previously treated,locally advanced or metastatic cholangiocarcinoma:a multicentre,open-label,phase 2 study［J］.Lancet Oncol，2020,21(5):671-684.
［12］GOYAL L,MERIC-BERNSTAM F,HOLLEBECQUE A,et al.Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma［J］.N Engl J Med,2023,388(3):228-239.
［13］FENG YH,SU WC,OH DY,et al.Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations［J］.J Clin Oncol,2022,40(4_suppl):430.
［14］ PIHA-PAUL SA,GOEL S,LIAO CY,et al.Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors:A phase Ib/II clinical trial［J］.J Clin Oncol,2023,41(suppl 16):3019.
［15］ ZHU AX,MACARULLA T,JAVLE MM,et al.Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation:the phase 3 randomized clinical ClarIDHy trial［J］.JAMA Oncol，2021,7(11):1669-1677.
［16］WAN PT,GARNETT MJ,ROE SM,et al.Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of BRAF［J］.Cell,2004,116(6):855-867.
［17］JAIN A,KWONG LN,JAVLE M.Genomic profiling of biliary tract cancers and implications for clinical practice［J］.Curr Treat Options Oncol,2016,17(11):58.
［18］MOEINI A,HABER PK,SIA D.Cell of origin in biliary tract cancers and clinical implications［J］.JHEP Rep,2021,3(2):100226.
［19］ZHANG W,ZHOU HY,WANG YY,et al.Systemic treatment of advanced or recurrent biliary tract cancer［J］.Biosci Trends,2020,14(5):328-341.
［20］HUANG WC,TSAI CC,CHAN CC.Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma［J］.J Formos Med Assoc,2017,116(6):464-468.
［21］SUBBIAH V,LASSEN U,LEZ E,et al.Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR):a phase 2,open-label,single-arm,multicentre basket trial［J］.Lancet Oncol，2020,21(9):1234-1243.
［22］MULLIGAN LM.RET revisited:expanding the oncogenic portfolio［J］.Nat Rev Cancer,2014,14(3):173-186.
［23］SUBBIAH V,CASSIER PA,SIENA S,et al.Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial［J］.Nat Med，2022,28(8):1640-1645.
［24］SUBBIAH V,WOLF J,KONDA B,et al.Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours(LIBRETTO-001):A phase 1/2,open-label,basket trial［J］.Lancet Oncol，2022,23:1261-1273.
［25］VAISHNAVI A,LE AT,DOEBELE RC.TRKing down an old oncogene in a new era of targeted therapy［J］.Cancer Discov,2015,5(1):25-34.
［26］SOLOMON JP,LINKOV I,ROSADO A,et al.NTRK fusion detection across multiple assays and 33,997 cases:diagnostic implications and pitfalls［J］.Mod Pathol,2020,33(1):38-46.
［27］ROSS JS,WANG K,GAY L,et al.New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing［J］.Oncologist,2014,19(3):235-242.
［28］DRILON A,LAETSCH TW,KUMMAR S,et al.Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children［J］.N Engl J Med，2018,378(8):731-739.
［29］DOEBELE RC,DRILON A,PAZ-ARES L,et al.Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours:integrated analysis of three phase 1-2 trials［J］.Lancet Oncol，2020,21(2):271-282.
［30］KIM HJ,YOO TW,PARK DI,et al.Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry:its prognostic implication in node-positive patients［J］.Ann Oncol,2007,18(5):892-897.
［31］JAVLE M,BORAD MJ,AZAD NS,et al.Pertuzumab and trastuzumab for HER2-positive,metastatic biliary tract cancer (MyPathway):a multicentre,open-label,phase 2a,multiple basket study［J］.Lancet Oncol,2021,22(9):1290-1300.
［32］黄娅娟,翟淑娟,刘洋,等.与肿瘤血管生成相关的信号通路的研究进展［J］.重庆医学,2018,47(A01):313-316.
HUANG YJ,ZHAI SJ,LIU Y,et al.Research progress of signaling pathways related to tumor angiogenesis［J］.Chongqing Medical Journal,2018,47(A01):313-316.
［33］ OKANO N,FURUSE J,UENO M,et al.Multicenter phase II trial of axitinib monotherapy for gemcitabine-based chemotherapy refractory advanced biliary tract cancer (AX-BC study)［J］.Oncologist,2021,26(2):97-201.
［34］ 曹园园,张文锐,张杰.雷莫芦单抗在肿瘤分子靶向治疗中的应用进展［J］.中国药房,2017,11(32):142-145.
CAO YY,ZHANG WR,ZHANG J.Application progress of ramucirumab in tumor molecular targeted therapy［J］.China Pharmacy,2017,11(32):142-145.
［35］ VILLANUEVA L，LWIN Z，CHUNG HCC，et al.Lenvatinib pluspembrolizumab for patients with previously treated biliary tractcancers in the multicohort phase 2 LEAP-005 study［J］.J Clin Oncol，2021，39（Suppl 3）：321.
［36］FOUASSIER L,MARZIONI M,AFONSO MB,et al.Signalling networks in cholangiocarcinoma:Molecular pathogenesis,targeted therapies and drug resistance［J］.Liver Int,2019,39 Suppl 1:43-62.
［37］PERSONENI N,LLEO A,PRESSIANI T,et al.Biliary tract cancers:molecular heterogeneity and new treatment options［J］.Cancers (Basel),2020,12(11):3370.
［38］HARDING JJ,KHALIL DN,FABRIS L,et al.Rational development of combination therapies for biliary tract cancers［J］.J Hepatol,2023,78(1):217-228.
［39］CHAE H,KIM D,YOO C,et al.Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer:DNA damage repair gene mutations as a predictive biomarker［J］.Eur J Cancer,2019,120:31-39.
［40］汤朝晖,陈家璐,刘深洋，等.靶免联合治疗在胆道恶性肿瘤转化中应用的意义［J］.中华外科杂志,2022,60(04):343-350.
TANG ZH,CHEN JL,LIU SY,et al.Significance of combination of targeted therapy and immunotherapy in conversion therapy of biliary tract cancer［J］.Chinese Journal of Surgery,2022,60(04):343-350.
［41］HAN S,LEE SY,WANG WW,et al.A perspective on cell therapy and cancer vaccine in biliary tract cancers (BTCs)［J］.Cancers (Basel),2020,12(11):3404.